共 50 条
- [31] Characterization of ipilimumab exposure-efficacy/safety response relationships in subjects with previously treated or untreated advanced melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Feng, YanGodfrey, C. J.Chu, Hui-MayMasson, EricWilliams, DaphneBerman, David MarkRoy, Amit
- [32] EXPOSURE-RESPONSE (E-R) ANALYSIS FOR SELECTION OF OPTIMAL DOSAGE REGIMEN OF ANIFROLUMAB IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 865 - 866Santiago, L. C.Wang, B.Brohawn, P.Wang, L.Illei, G.Roskos, L.
- [33] Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Song XuyangKelley, Robin KateKhan, AnisStandifer, NathanKrishna, RajeshLiu, LucyWang KunGreen, MichelleMcCoon, PatriciaNegro, AlejandraHe, PhilipNarwal, RajeshAbou-Alfa, Ghassan K.
- [34] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Hogg, DavidChapman, Paul B.Sznol, MarioLao, Christopher D.Gonzalez, ReneDaniels, Gregory A.Smylie, MichaelKudchadkar, Ragini ReineyThompson, John A.Sharfman, William HowardAtkins, Michael B.Pavlick, Anna C.Jiang, JoelAvila, AlexandreDemelo, SheenaHodi, F. Stephen
- [35] Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Wang, X.Hochhaus, A.Kantarjian, H. M.Agrawal, S.Roy, A.Pfister, M.Chen, T.Bleickardt, E.Nicaise, C.Shah, N.
- [36] Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerCTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (05): : 459 - 469Grevel, JoachimJentsch, GarritAustin, RupertPrins, Nicolaas H.Lettieri, JohnMitchell, DavidHuang, FunanBrose, Marcia S.Schlumberger, MartinMeinhardt, GeroldPena, Carol E. A.Ploeger, Bart A.
- [37] Exposure-response (E-R) relationship of ABT-263-induced thrombocytopenia in cancer patients in phase 1 studiesMOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)Xiong, HaoNoertersheuser, Peter A.Pradhan, Rajendra S.Krivoshik, Andrew P.Humerickhouse, RodAwni, Walid
- [38] EXPLORING ENDPOINT CORRELATION BETWEEN PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PREVIOUSLY UNTREATED METASTATIC MELANOMA USING PSEUDO INDIVIDUAL PATIENT DATA (IPD)VALUE IN HEALTH, 2022, 25 (12) : S20 - S20Kanters, S.Kurt, M.Moshyk, A.Leung, L.
- [39] Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell LymphomaADVANCES IN THERAPY, 2022, 39 (01) : 598 - 618Samineni, DivyaHuang, WeizeGibiansky, LeonidDing, HaoZhang, RongLi, ChunzeSinha, ArijitRajwanshi, RichaHumphrey, KathrynBazeos, AlexandraSalem, Ahmed HamedMiles, Dale
- [40] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)BLOOD, 2008, 112 (11) : 125 - 125Hallek, MichaelFingerle-Rowson, GuenterFink, Anna-MariaBusch, RaymondeMayer, JiriHensel, ManfredHopfinger, GeorgHess, Georgvon Gruenhagen, UlrichBergmann, Manuela A.Catalano, JohnZinzani, Pier LuigiCappio, Federico CaligarisSeymour, John FrancisBerrebi, AlainJaeger, UlrichCazin, BrunoTrneny, MarekWestermann, AnneWendtner, Clemens-MartinEichhorst, Barbara F.Staib, PeterBoettcher, SebastianRitgen, MatthiasStilgenbauer, StephanMendila, MyriamKneba, MichaelDoehner, HartmutFischer, Kirsten